Skip to main
PSNL
PSNL logo

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc. demonstrates a strong outlook, driven by compelling clinical data indicating that certain biomarkers, such as minimal residual disease (MRD) status, correlate with improved treatment outcomes and patient survival rates. The positive results from studies utilizing the osimertinib therapy suggest actionable insights for personalized treatment approaches, enhancing the utility of Personalis's genomic sequencing services. Additionally, the anticipated reimbursement application related to lung cancer, supported by successful outcomes from the NeoADAURA study, positions Personalis favorably within the evolving landscape of oncological therapeutics, potentially driving revenue growth.

Bears say

Personalis Inc has been facing significant financial challenges, including rising operational costs and declining revenue growth, which may hinder its ability to sustain profitability in the competitive genomic sequencing market. The company's reliance on a limited product range and its struggle to secure long-term partnerships with pharmaceutical firms underscore concerns regarding its market position and future scalability. Additionally, ongoing investments in research and development, while necessary for innovation, are putting further strain on cash flow in the face of increasing competition and economic pressures.

Personalis Inc (PSNL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.